Abstract As a promising tool in clinical evaluation of radiopharmaceuticals, PET has been widely used in the molecular imaging pipeline, providing critical information for the decision-making process in each step of drug development. The advent of total body PET, characterized by its extended axial field of view and substantially increased sensitivity, represents a major technological leap. This innovation facilitates the direct translation of preclinical findings to human studies, enabling comprehensive, whole-body dynamic imaging for precise pharmacokinetic and dosimetric assessments in first-in-human trials. Furthermore, its high quantitative accuracy allows for the nuanced comparison of “me-too” or “me-better” compounds, revealing subtle yet critical differences in their in vivo behavior. This commentary reviews how these unique capabilities are transforming the clinical evaluation of radiopharmaceuticals, effectively bridging the gap between preclinical discovery and clinical application and accelerating the drug development pipeline.
Meng et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: